Skip to search formSkip to main contentSkip to account menu

ABY-025

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Peptide FragmentsStaphylococcal Protein A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Diagnostic HER2-binding radiopharmaceutical, [68Ga]Ga-ABY-025, for routine clinical use in breast cancer patients.
[68Ga]Ga-ABY-025/PET-CT targeting human epidermal growth factor receptor type 2 (HER2) has demonstrated its potential clinical… 
Highly Cited
2016
Highly Cited
2016
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Purpose: Positron Emission Tomography (PET) imaging of HER2 expression could potentially be used to select patients for HER2… 
2016
2016
17AAG-induced internalisation of HER2-specific Affibody molecules
The geldanamycin derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) is known to induce internalisation and degradation of… 
2013
2013
Abstract P4-01-17: Molecular imaging and quantification of HER-2 status in metastatic breast cancer by using 68Ga-ABY-025/PET-CT
Background: Molecular imaging, in particular, positron emission tomography (PET) provides unique possibility to non-invasively… 
2011
2011
Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2…
2011
2011
Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell…
The treatment of disseminated prostate cancer remains a great challenge in current oncology practice. The proliferation of… 
2011
2011
P2-09-01: First-in-Human Whole-Body HER2−Receptor Mapping Using Affibody Molecular Imaging.
Background: ABY-025 is a member of a promising class of scaffold-based antibody alternatives known as Affibody molecules with… 
Highly Cited
2010
Highly Cited
2010
Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold
Overexpression of the human epidermal growth factor receptor type 2 (HER2) in breast carcinomas predicts response to trastuzumab… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)